Despite attempts to solve problems with shortages of brand-name medicines in the UK, the issue is taking up more of pharmacists’ time, is far from being solved and may be getting worse according to an online stock survey carried out by pharmacists organisation Chemist+Druggist.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- FDA approves aflibercept biosimilar Eydenzelt and label expansion for adalimumab biosimilar Yuflyma
- ANVISA approves biosimilars for denosumab, trastuzumab, and aflibercept
- Biosimilars referencing Amgen’s Neulasta and Neupogen launch in Canada and US
- EMA recommends approval for nine biosimilars
- MORE EDITORIAL SECTIONS
- Search




Post your comment